References

References1. CDC Fact Sheet 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed August 5, 2008.2. Honeycutt AA, Boyle JP, Broglio KR, et al. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci 2003;6:155–164.HoneycuttAA]]BoyleJP]]BroglioKR&etal;A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050.Health Care Manag Sci20036155-1643. EDIC Study Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159–2167.EDIC Study GroupSustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.JAMA20032902159-21674. Liakishev AA. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Results of the DCCT/EDIC study. Kardiologiia 2006;46:73.LiakishevAAIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Results of the DCCT/EDIC study.Kardiologiia200646735. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.&NA;Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet1998352837-8536. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(suppl 2):B21–B29.ShichiriM]]KishikawaH]]OhkuboY&etal;Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.Diabetes Care200023B21-B297. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diab Vasc Dis Res 2007;4(suppl 3):S5–S8.ChapmanMJMetabolic syndrome and type 2 diabetes: lipid and physiological consequences.Diab Vasc Dis Res20074S5-S88. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–431.SelvinE]]MarinopoulosS]]BerkenblitG&etal;Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.Ann Intern Med2004141421-4319. Niskanen L, Karjalainen J, Siitonen O, et al. Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis. J Intern Med 1994;236:263–270.NiskanenL]]KarjalainenJ]]SiitonenO&etal;Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis.J Intern Med1994236263-27010. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type 2 diabetes: a progressive disease. UK Prospective Diabetes Study Group [erratum in Diabetes 1996;45:1655]. Diabetes 1995;44:1249–1258.11. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988–1992.LilliojaS]]MottDM]]SpraulM&etal;Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians.N Engl J Med19933291988-199212. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342–1349.NathanDMClinical practice. Initial management of glycemia in type 2 diabetes mellitus.N Engl J Med20023471342-134913. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(suppl 1):1–68.AACE Diabetes Mellitus Clinical Practice Guidelines Task ForceAmerican association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.Endocr Pract2007131-6814. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care 2008;31(suppl 1):S12–S54.American Diabetes AssociationStandards of medical care in diabetes—2008.Diabetes Care200831S12-S5415. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17–20.KoroCE]]BowlinSJ]]BourgeoisN&etal;Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.Diabetes Care20042717-2016. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403–408.HarrisMI]]EastmanRC]]CowieCC&etal;Racial and ethnic differences in glycemic control of adults with type 2 diabetes.Diabetes Care199922403-40817. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 2006;144:465–474.SaaddineJB]]CadwellB]]GreggEW&etal;Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002.Ann Intern Med2006144465-47418. Kilpatrick E. The challenge of poor glycaemic control among people with diabetes. Int J Clin Pract 2007;61:1054–1057.KilpatrickEThe challenge of poor glycaemic control among people with diabetes.Int J Clin Pract2007611054-105719. Matthews DR, Cull CA, Stratton IM, et al; UKPDS 26. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297–303.MatthewsDR]]CullCA]]StrattonIM&etal;UKPDS 26Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.Diabet Med199815297-30320. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963–1972 and Diabetologia 2006;49:1711–1721.21. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541–549.DeFronzoRA]]GoodmanAMEfficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.N Engl J Med1995333541-54922. Zavaroni I, Bonini L, Gasparini P, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999;48:989–994.ZavaroniI]]BoniniL]]GaspariniP&etal;Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited.Metabolism199948989-99423. Gough SC, Frandsen KB, Toft AD. Failure of insulin monotherapy in patients with type 2 diabetes: a population-based study [abstract]. Diabetes 2006;55(suppl 1):A114.GoughSC]]FrandsenKB]]ToftADFailure of insulin monotherapy in patients with type 2 diabetes: a population-based study [abstract].Diabetes200655A11424. Wright A, Burden AC, Paisey RB, et al; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330–336.WrightA]]BurdenAC]]PaiseyRB&etal;U.K. Prospective Diabetes Study GroupSulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).Diabetes Care200225330-33625. Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 2005;22:1379–1385.PeyrotM]]RubinRR]]LauritzenT&etal;Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study.Diabet Med2005221379-138526. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(suppl 3):S18–S24.KorytkowskiMWhen oral agents fail: practical barriers to starting insulin.Int J Obes Relat Metab Disord200226S18-S2427. Brunton SA, Davis SN, Renda SM. Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone 2006;8(suppl 2):S19–S26.BruntonSA]]DavisSN]]RendaSMOvercoming psychological barriers to insulin use in type 2 diabetes.Clin Cornerstone20068S19-S2628. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–2679.PeyrotM]]RubinRR]]LauritzenT&etal;Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.Diabetes Care2005282673-267929. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006;8:58–66.GarberAJ]]WahlenJ]]WahlT&etal;Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study).Diabetes Obes Metab2006858-6630. Brunton SA. Insulin regimens for type 2 diabetes mellitus. J Fam Pract 2006;55(suppl):S10–S17.BruntonSAInsulin regimens for type 2 diabetes mellitus.J Fam Pract200655S10-S1731. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164–174.MeneghiniLWhy and how to use insulin therapy earlier in the management of type 2 diabetes.South Med J2007100164-17432. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881–885.MonnierL]]LapinskiH]]ColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).Diabetes Care200326881-88533. Monnier L, Collette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263–269.MonnierL]]ColletteC]]DunseathGJ&etal;The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes.Diabetes Care200730263-26934. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006;32(suppl 1):9S–18S.MeeceJDispelling myths and removing barriers about insulin in type 2 diabetes.Diabetes Educ2006329S-18S35. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511–522.ZimmermanBRSulfonylureas.Endocrinol Metab Clin North Am199726511-52236. Simonson DC, Ferrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984;33:838–845.SimonsonDC]]FerranniniE]]BevilacquaS&etal;Mechanism of improvement in glucose metabolism after chronic glyburide therapy.Diabetes198433838-84537. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55(5 suppl 1):S20–S27.Del PratoS]]PulizziNThe place of sulfonylureas in the therapy for type 2 diabetes mellitus.Metabolism200655S20-S2738. Kilo C, Meenan A, Bloomgarden Z. Glyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus. Clin Ther 1992;14:801–812.KiloC]]MeenanA]]BloomgardenZGlyburide versus glipizide in the treatment of patients with non-insulin-dependent diabetes mellitus.Clin Ther199214801-81239. Maedler K, Carr RD, Bosco D, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501–506.MaedlerK]]CarrRD]]BoscoD&etal;Sulfonylurea induced beta-cell apoptosis in cultured human islets.J Clin Endocrinol Metab200590501-50640. Henry RR. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 1998;105(1A):20S–26S.HenryRRType 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention.Am J Med19981051A20S-26S41. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119–124.GarrattKN]]BradyPA]]HassingerNL&etal;Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.J Am Coll Cardiol199933119-12442. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19:789–830.MeinertCL]]KnatterudGL]]ProutTE&etal;A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes.Diabetes197019789-83043. Mocanu MM, Maddock HL, Baxter GF, et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001;103:3111–3116.MocanuMM]]MaddockHL]]BaxterGF&etal;Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.Circulation20011033111-311644. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002;51:808–812.ScognamiglioR]]AvogaroA]]Vigili de KreutzenbergS&etal;Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.Diabetes200251808-81245. Meier JJ, Gallwitz B, Schmidt WE, et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90:9–12.MeierJJ]]GallwitzB]]SchmidtWE&etal;Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?Heart2004909-1246. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119–124.MosesR]]SlobodniukR]]BoyagesS&etal;Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.Diabetes Care199922119-12447. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660–1665.HortonES]]ClinkingbeardC]]GatlinM&etal;Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.Diabetes Care2000231660-166548. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18(suppl 2):S10–S15.HaunerHThe mode of action of thiazolidinediones.Diabetes Metab Res Rev200218S10-S1549. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.KahnSE]]HaffnerSM]]HeiseMA&etal;Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.N Engl J Med20063552427-244350. Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA1c: a meta-analysis of published randomized clinical trials. Curr Med Res Opin 2006;22:2267–2278.PhatakHM]]YinDDFactors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA1c: a meta-analysis of published randomized clinical trials.Curr Med Res Opin2006222267-227851. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.NissenSE]]WolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med20073562457-247152. Lipscombe LL, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634–2643.LipscombeLL]]GomesT]]LévesqueLE&etal;Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.JAMA20072982634-264353. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194–206.AmoriRE]]LauJ]]PittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.JAMA2007298194-20654. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360–372.InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: scientific review.JAMA2002287360-37255. Nathan DM. Finding new treatments for diabetes–how many, how fast… how good? N Engl J Med 2007;356:437–440.NathanDMFinding new treatments for diabetes–how many, how fast… how good?N Engl J Med2007356437-44056. Lub R, Denig P, van den Berg PB, et al. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus. Br J Clin Pharmacol 2006;62:660–665.LubR]]DenigP]]van den BergPB&etal;The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus.Br J Clin Pharmacol200662660-66557. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–117.OhkuboY]]KishikawaH]]ArakiE&etal;Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.Diabetes Res Clin Pract199528103-11758. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304–309.ReichardP]]NilssonBY]]RosenqvistUThe effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus.N Engl J Med1993329304-30959. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028–1032.RyanEA]]ImesS]]WallaceCShort-term intensive insulin therapy in newly diagnosed type 2 diabetes.Diabetes Care2004271028-103260. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with microvascular and macrovascular complications of type 2 diabetes (UPDS 35): prospective observational study. BMJ 2000;321:405–412.StrattonIM]]AdlerAI]]NeilHA&etal;Association of glycaemia with microvascular and macrovascular complications of type 2 diabetes (UPDS 35): prospective observational study.BMJ2000321405-41261. Roper NA, Bilous RW, Kelly WF, et al. Cause-specific mortality in a population with diabetes: south tees diabetes mortality study. Diabetes Care 2002;25:43–48.RoperNA]]BilousRW]]KellyWF&etal;Cause-specific mortality in a population with diabetes: south tees diabetes mortality study.Diabetes Care20022543-4862. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research GroupIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.N Engl J Med20053532643-265363. Genuth S. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract 2006;12(suppl 1):34–41.GenuthSInsights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.Endocr Pract20061234-4164. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554–559.RosenstockJ]]SugimotoD]]StrangeP&etal;Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.Diabetes Care200629554-55965. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116:230–235.AljabriK]]KozakSE]]ThompsonDMAddition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.Am J Med2004116230-23566. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in type 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007;50:1140–1147.UK Hypoglycaemia Study GroupRisk of hypoglycaemia in type 1 and 2 diabetes: effects of treatment modalities and their duration.Diabetologia2007501140-114767. McFarlane SI, Chaiken RL, Hirsch S, et al. Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10–16.McFarlaneSI]]ChaikenRL]]HirschS&etal;Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function.Diabet Med20011810-1668. Scarlett JA, Gray RS, Griffin J, et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 1982;5:353–363.ScarlettJA]]GrayRS]]GriffinJ&etal;Insulin treatment reverses the insulin resistance of type II diabetes mellitus.Diabetes Care19825353-36369. LeRoith D, Fonseca V, Vinik A. Metabolic memory in diabetes–focus on insulin. Diabetes Metab Res Rev 2005;21:85–90.LeRoithD]]FonsecaV]]VinikAMetabolic memory in diabetes–focus on insulin.Diabetes Metab Res Rev20052185-9070. Kowluru RA, Kanwar M, Kennedy A. Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res 2007;2007:21976.KowluruRA]]KanwarM]]KennedyAMetabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries.Exp Diabetes Res200720072197671. Riddle MC. Timely initiation of basal insulin. Am J Med 2004;116(suppl 3A):3S–9S.RiddleMCTimely initiation of basal insulin.Am J Med20041163S-9S72. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes [erratum in: Diabetes Care 2007;30:1035]. Diabetes Care 2006;29:1269–1274.73. Holman RR, Thorne KI, Farmer AJ, et al; 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–1730.HolmanRR]]ThorneKI]]FarmerAJ&etal;4-T Study GroupAddition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.N Engl J Med20073571716-173074. Bebakar WM, Chow CC, Kadir KA, et al; BIAsp-3021 Study Group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:724–732.BebakarWM]]ChowCC]]KadirKA&etal;BIAsp-3021 Study GroupAdding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes.Diabetes Obes Metab20079724-73275. Levy P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. MedGenMed 2007;9:12.LevyPInsulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes.MedGenMed200791276. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005;65:325–340.OiknineR]]BernbaumM]]MooradianADA critical appraisal of the role of insulin analogues in the management of diabetes mellitus.Drugs200565325-34077. Hirsch IB, Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005;23:78–86.HirschIB]]BergenstalRM]]ParkinCG&etal;A real-world approach to insulin therapy in primary care practice.Clin Diabetes20052378-8678. Raslová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes [erratum in Diabetes Res Clin Pract 2006;72:112]. Diabetes Res Clin Pract 2004;66:193–201.79. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622–629.HermansenK]]FontaineP]]KukoljaKK&etal;Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.Diabetologia200447622-62980. Simonson DC, Kourides IA, Feinglos M, et al. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care 1997;20:597–606.SimonsonDC]]KouridesIA]]FeinglosM&etal;Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.Diabetes Care199720597-60681. Stenman S, Melander A, Groop PH, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993;118:169–172.StenmanS]]MelanderA]]GroopPH&etal;What is the benefit of increasing the sulfonylurea dose?Ann Intern Med1993118169-17282. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491–497.GarberAJ]]DuncanTG]]GoodmanAM&etal;Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.Am J Med1997103491-49783. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997;103:483–490.HoffmannJ]]SpenglerMEfficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.Am J Med1997103483-49084. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16:621–629.NagiDK]]YudkinJSEffects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.Diabetes Care199316621-62985. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996;19:64–66.GrantPJThe effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.Diabetes Care19961964-6686. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605–1611.AronoffS]]RosenblattS]]BraithwaiteS&etal;Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care2000231605-161187. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes [erratum in J Clin Endocrinol Metab 2001;86:1659 and J Clin Endocrinol Metab 2002;2:iv]. J Clin Endocrinol Metab 2001;86:280–288.88. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes [erratum in Diabetes Care 2001;24:973]. Diabetes Care 2001;24:308–315.89. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998;35:34–40.FischerS]]HanefeldM]]SpenglerM&etal;European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.Acta Diabetol19983534-4090. Santeusanio F, Ventura MM, Contandini S, et al. Efficacy and safety of two different doses of acarbose in non-insulin-dependent diabetic patients treated by diet alone. Diabetes Nutr Metab 1993;6:147–154.SanteusanioF]]VenturaMM]]ContandiniS&etal;Efficacy and safety of two different doses of acarbose in non-insulin-dependent diabetic patients treated by diet alone.Diabetes Nutr Metab19936147-15491. Januvia (sitagliptin phosphate) Package Insert. Merck and Co, Inc, 2006. Available at: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_ppi.pdf. Accessed February 20, 2008.92. Symlin (pramlintide acetate) Injection Package Insert. Amylin Pharmaceuticals, Inc, 2005. Available at: http://www.symlin.com/pdf/SYMLIN-pi-combined.pdf. Accessed February 20, 2008.93. Byetta (exenatide) Injection Package Insert. Amylin Pharmaceuticals, 2005. Available at: http://pi.lilly.com/us/byetta-pi.pdf. Accessed February 20, 2008.94. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40–47.WolffenbuttelBH]]GomisR]]SquatritoS&etal;Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients.Diabet Med20001740-4795. Schneider R, Egan J, Houser V, et al. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes [abstract]. Diabetes 1999;48:A106.SchneiderR]]EganJ]]HouserV&etal;Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes [abstract].Diabetes199948A10696. Willms B, Ruge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study [erratum in Diabet Med 2000;17:332&rs